Recombinant Microorganisms for Mevalonate Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing mevalonate and isoprenoids are inefficient, often requiring complex organic synthesis or extraction from biological materials, which are costly and yield low amounts due to the complex nature of these molecules and the use of toxic solvents, limiting their practical application.
Innovation Solution
Engineered recombinant microorganisms with modulated enzyme activities such as citrate synthase, phosphotransacetylase, and pyruvate dehydrogenase to increase carbon flux towards mevalonate production, incorporating nucleic acids encoding mevalonate pathway polypeptides and isoprene synthase, enhancing the yield of mevalonate, isoprene, and isoprenoids.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional extraction or organic synthesis methods are used to obtain mevalonate and isoprenoids, then the production can be achieved, but the process requires toxic solvents, complex multiple steps, and yields low amounts due to the complex nature of these molecules
Solution Approach 1:
The patent employs recombinant microorganisms that contain the complete mevalonate pathway and isoprenoid biosynthesis machinery within their own cellular systems. These engineered cells autonomously convert simple substrates like glucose into mevalonate and isoprenoids through their endogenous enzymatic pathways, eliminating the need for external toxic solvents and complex synthetic steps. The microorganisms serve themselves by using their own metabolic networks to produce the target compounds.
Solution Approach 2:
The patent replaces mechanical/chemical extraction systems with biological synthesis systems. Instead of using toxic solvents to extract isoprenoids from biological materials or employing multi-step organic synthesis, the invention uses genetically engineered microorganisms to biologically synthesize mevalonate and isoprenoids. This substitution of chemical-mechanical processes with biological processes simplifies the overall system and eliminates the need for harmful chemicals.
2Productivity
If conventional extraction methods are used, then mevalonate and isoprenoids can be obtained, but toxic solvents are required which limit practical application
Solution Approach 1:
The patent replaces chemical extraction methods that require toxic solvents with biological synthesis methods using engineered microorganisms. The microorganisms produce mevalonate and isoprenoids through their natural metabolic pathways, eliminating the need for toxic solvents entirely. This substitution of chemical extraction with biological production resolves the harmful factor while maintaining or improving productivity.
Solution Approach 2:
The patent converts the microorganism's natural metabolic capabilities into a beneficial production system. By engineering the mevalonate pathway and isoprenoid biosynthesis into microorganisms, the invention transforms these cells into factories that produce high-value compounds. The natural biological processes that once required toxic extraction are now harnessed to directly produce the desired products, converting a potential harm (need for toxic solvents) into a benefit (green biological production).
3Quantity of substance
If biological materials are used for extraction, then mevalonate and isoprenoids can be obtained, but only minute amounts are present making large-scale production difficult
Solution Approach 1:
The engineered microorganisms autonomously channel carbon flux from simple substrates like glucose through the mevalonate pathway to produce mevalonate and isoprenoids. The cells use their own metabolic machinery to synthesize these compounds de novo, rather than relying on pre-existing minute amounts in natural biological materials. This self-service capability enables high-yield production that is not limited by the natural concentration of these compounds in source materials.
Solution Approach 2:
The patent fundamentally changes the production parameter from extracting trace amounts from natural materials to synthesizing large amounts through engineered metabolic pathways. By introducing and overexpressing key enzymes of the mevalonate pathway (such as HMG-CoA reductase) and isoprenoid biosynthesis genes in recombinant microorganisms, the system transforms the concentration parameter, enabling production of mevalonate and isoprenoids at levels suitable for commercial applications rather than trace amounts.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Significantly increases the production of mevalonate, isoprene, and isoprenoids, improving yield and reducing the need for toxic solvents, making these compounds more viable for commercial use.
Implementation Method 1
The conversion of acetyl-CoA to mevalonate can be catalyzed by the thiolase, HMG-CoA synthase and the HMG-CoA reductase activities of the upper mevalonate-dependent biosynthetic pathway (MVA pathway)
Implementation Method 2
R-Mevalonate is an intermediate of the mevalonate-dependent biosynthetic pathway that converts acetyl-CoA to isopentenyl diphosphate and dimethylallyl diphosphate
Data Source
AI summary
The invention features compositions and methods for the increased production of mevalonate, isoprene, isoprenoid precursor molecules, and/or isoprenoids in microorganisms by engineering a microorganism for increased carbon flux towards mevalonate production in the following enzymatic pathways: (a) citrate synthase, (b) phosphotransacetylase, (c) acetate kinase, (d) lactate dehydrogenase, (e) malic enzyme, and (f) pyruvate dehydrogenase such that one of more of the enzyme activity is modulated. In addition, production of mevalonate, isoprene, isoprenoid precursor molecules, and/or isoprenoids can be further enhanced by the heterologous expression of the mvaE and mvaS genes (such as, but not limited to, mvaE and mvaS genes from the organisms Listeria grayi DSM 20601, Enterococcus faecium, Enterococcus gallinarum EG2, and Enterococcus casseliflavus).